Skip to main content
. 2019 Nov 4;11(11):1723. doi: 10.3390/cancers11111723

Table 1.

Randomized control trials since 2014 assessing bevacizumab use in newly diagnosed glioblastoma.

First Author (Year) Level of Study n Median Age (Years) Duration of Follow-up (Months) Treatment Control Prior Treatment
1 Balana [14] (2016) I Tx: 49 Control: 53 Tx: 62.9 Control: 62.0 >18.0 BEV + TMZ TMZ Biopsy only
2 Carlson [15] (2015) I Tx: 30 Control: 26 Tx: 56.5 Control: 60.5 Tx: 14.7 Control: 13.9 BEV + Hypo-IMRT + TMZ Hypo-IMRT + TMZ Biopsy/Sx
3 Chauffert [16] (2014) I Tx: 60 Control: 60 Tx: 60.2 Control: 60.9 BEV + IRI + RT + TMZ RT + TMZ Biopsy only
4 Chinot [9] (2014) I Tx: 458 Control: 463 Tx: 57.0 Control: 56.0 Tx: 14.4 Control: 13.7 BEV + RT + TMZ PLA + RT + TMZ Biopsy/Sx
5 Gilbert [10] (2014) I Tx: 312 Control: 309 Tx: 59.0 Control: 57.0 20.5 BEV + RT + TMZ PLA + RT + TMZ Biopsy/Sx
6 Herrlinger [17] (2016) I Tx: 116 Control: 54 Tx and Control: 56.0 BEV + IRI + RT RT + TMZ Biopsy/Sx
7 Wirsching [18] (2018) I Tx: 50 Control: 25 Tx: 70 Control: 70 BEV + Hypo-RT Hypo-RT Sx, steroids

Abbreviations: Tx, treatment; BEV, bevacizumab; TMZ, temozolomide; RT, radiotherapy; Sx, resective surgery; Hypo-IMRT, hypofractionated-intensity modulated radiotherapy; IRI, irinotecan; PLA, placebo; hypo-RT, hypofractionated radiotherapy. All studies administered BEV intravenously at 10 mg/kg every two weeks, starting at varying time points within treatment plan.